Human papillomavirus (HPV) infection is causally related to a subset of oropharyngeal carcinomas (OPC) and is linked to a more favourable prognosis compared to HPV-negative OPC. The mechanisms underlying this effect on prognosis are not fully understood, but interactions with the tumour microenvironment may be pivotal. Here, we investigated the role of the tumour microenvironment in HPV-positive compared to HPV-negative cancer using 2D and 3D modelling of OPC interactions with stromal fibroblasts. HPV-negative, but not HPV-positive, OPC-derived cell lines induced a rapid fibroblast secretory response that supported 2D cancer cell migration and invasion in vitro. Array profiling of this HPV-negative induced fibroblast secretome identified hepatocyte growth factor (HGF) as the principal secreted factor that promoted cancer cell migration. The interaction between HPV-negative cell lines and fibroblasts in 2D was prevented using c-Met (HGF receptor) inhibitors, which further restricted both HPV-negative and positive cell invasion in 3D co-culture models. Furthermore, we discovered a synergistic relationship between HGF and IL-6 in the support of migration that relates JAK activation to HGF responsiveness in HPV-negative lines. In summary, our data show significant differences in the interactions between HPV-positive and HPV-negative OPC cells and stromal fibroblasts. In addition, we, provide in vitro evidence to support the clinical application of c-MET inhibitors in the control of early HPV-negative OPC.
Introduction
Oropharyngeal carcinoma (OPC) has become a major public health concern as a result of the recent surge of disease linked to human papillomavirus (HPV) (1, 2) . Indeed, OPC now represents the most common malignancy encountered by the head and neck oncologist (3) . Much effort has been invested in tailoring therapeutic strategies towards the emerging HPVpositive subset of tumours due to their favourable prognosis and occurrence in younger individuals, whom may therefore suffer greater long-term sequelae of aggressive therapy. Whilst there is an urgent need to optimize management strategies in HPV-positive disease, the poor prognosis of HPV-negative OPC should not be overlooked. Moreover, a recent UK-based study suggests that as well as the well-publicized increase in HPVpositive disease, incidence of HPV-negative OPC is also increasing (4) . Comparison of the biology of HPV-positive and -negative disease may offer insights into prognostic determinants, and therefore how best to deliver targeted therapeutics to manage HPV-negative disease.
Although preservation of wild-type TP53, reduced genetic aberration and tumour radiosensitivity account for a significant proportion of the prognostic variation between HPVpositive and -negative disease, much remains unknown about the overall pathogenesis of these malignancies (5) (6) (7) . Little data is available on the role of the tumour microenvironment in OPC and how this may relate to a HPV-positive tumour status. Recent work has illustrated the significant role of the microenvironment in supporting the progression of poorly prognosticating head and neck cancer, and how this relates to loss of p16 and p53 (8) . HPV-positive tumours characteristically display upregulated p16 expression and carry wild-type TP53 as a consequence of viral oncogenes E6 and E7 functionally sequestrating important tumour suppressors-thereby abrogating the evolutionary pressure for genetic aberration during tumorigenesis. HPV-positive disease may therefore derive prognostic benefit from a lack of microenvironment interactions attributable to tumour p16 and p53 status, or as a result of viral evasion of the immune system through suppression of inflammatory signalling (9) (10) (11) . Indeed, HPV is regarded as a strictly epitheliotropic virus (12) , and evasion of connective tissue exposure to the virus appears necessary in order to avoid clearance.
The purpose of this study was to investigate the effects of the secretome of both HPV-positive and HPV-negative OPC cell lines on oral and tonsillar fibroblasts harvested from normal tissue. We demonstrate that HPV-negative tumour lines have the ability to induce fibroblasts to develop a secretory phenotype supportive of tumour migration and invasion. Specifically, we show that HPV-negative cell line migration is promoted by inducing fibroblast secretion of a combination of HGF and IL-6, and that 3D invasion can be restrained by the clinically available c-MET inhibitor, foretinib.
Materials and methods

Cell lines and culture conditions
OPC cell lines UD SCC02, UPCI SCC072, UPCI SCC089 and UPCI SCC090 were received under Material Transfer Agreement from Prof. S. Gollin, University of Pittsburgh School of Public Health, Pittsburgh, PA. HPV status was confirmed by PCR using a commercially-available HPV16 E1 probe (Applied Biosystems, UK) in addition to a custom HPV16 E6 probe (13) . Short tandem repeat profiling was undertaken to confirm cell line authenticity. A summary of cell lines used is given in Supplementary Table 1, available at Carcinogenesis Online (14) (15) (16) (17) (18) (19) .
Fibroblast cultures were derived from oral (DENOF08) and tonsillar (NTF01, NTF06) explant cultures as described previously (20) , using surplus tissue retrieved from patients with written, informed consent during routine oral and ENT surgery with ethical approval (09/H1308/66). Both fibroblasts and OPC cell lines, as well as Hela and HepG2 cells, were cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal calf serum, with 2 mM L-glutamine and 50 IU penicillin and 50 μg ml −1 streptomycin ('normal media') and incubated under standard conditions (5% CO 2 , 37°C). All cell cultures were subject to regular mycoplasma testing.
Collection of conditioned medium
Cell lines were grown to approximately 70-90% confluence in 75 cm 2 flasks, washed in phosphate-buffered saline (PBS) and incubated with fresh normal media for 24 h. Conditioned medium (CM) was then retrieved, centrifuged at 3000 rpm for 5 min to remove cell debris and stored at −20°C. The remaining cells were counted and CM normalized to a concentration of 3 × 10 6 cells ml −1 .
Oral and tonsillar fibroblast cultures (passage 7) were grown to confluence in 75 cm 2 flasks, washed in PBS and incubated with either OPC cell line CM or normal media control for 24 h. Flasks were then washed in PBS and incubated with normal media for a further 24 hours in order to collect a 'stimulated' fibroblast CM. CM was then retrieved, centrifuged at 3000 rpm for 5 min and stored at −20 o C. Remaining cells were counted in order to confirm an equal number of cells in each experiment post-stimulation. The process of OPC cell line/fibroblast conditioned media collection is summarized in Supplementary Figure A. Re-exposure of cell lines to stimulated fibroblast medium Each cell line was exposed to either unstimulated fibroblast CM or media derived from fibroblasts stimulated by the respective cell line CM in the subsequent experiments.
MTS assay
Proliferation of cell lines in the presence of either respective stimulated fibroblast media or unstimulated fibroblast CM control was assessed by means of MTS proliferation assay. Cells were grown to 70-80% confluence, counted using a haemocytometer, centrifuged at 1000 rpm for 5 min, resuspended in stimulated fibroblast or control media, re-counted and seeded at a density of 1 × 10 4 cells per well into a 96-well plate. Wells were incubated at 37 o C in a 5% CO 2 environment, and measurements taken at baseline, 24, 48, 72 and 96 h. At each time point, respective triplicate wells were rinsed with 100 μl PBS, then 100 μl normal media added. MTS (20 μl, CellTiter, Promega, Madison) was then added to each well, and incubated for 1.5 h. Optical density at 492 nm was then measured using a plate reader (Tecan Infinite M200).
2D cell exclusion zone migration assay
ORIS assay plates (AMS Biotechnology, Oxford, UK) were prepared under sterile conditions according to the manufacturer's instructions. 100 μl of each cell line suspension at a pre-optimized concentration for well confluency was pipetted into respective ORIS assay wells and left overnight to adhere. Following cell adherence and confirmation of well confluency, optimized concentrations of mitomycin C in normal media were prepared from snap-frozen stock aliquots stored at −80 o C. Optimization of mitomycin C-induced growth arrest was undertaken for each cell line using flow cytometric analysis of CellTrace TM (Invitrogen, Life Technologies, Paisley, UK-data not shown). Silicone stoppers were removed from assay wells and normal media carefully aspirated, wells washed with PBS and mitomycin C added before incubation for 3.5 h at 37°C in the dark. Baseline void photomicrographs were taken, assay wells washed in PBS and either stimulated fibroblast conditioned media or unstimulated fibroblast conditioned media control added. Assay plates were incubated for either 20 h (UPCI SCC089-a rapidly migrating line under basal conditions) or 48 h (UD SCC02, UPCI SCC072, UPCI SCC090) to allow migration to occur, and endpoint photomicrographs taken. Area of exclusion zone closure over the experimental period was measured using ImageJ (NIH).
Assays were repeated using recombinant human CTGF, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, HGF, IL-6, IL-8, OPG and OSM (Insight Biotechnology, Wembley, UK) in place of stimulated fibroblast media. Where indicated, dimethyl sulfoxide (DMSO) or foretinib (0.4, 4 or 40 nM)/ruxolitinib (1 μM) was added to conditioned media over the period of migration and migration assays performed as described.
Cytokine array
Serum-free conditioned media were collected from cell lines and stimulated fibroblasts as described above and soluble factors analysed by 
Flow cytometry
Cell lines UD SCC2, UPCI SCC072, UPCI SCC089, UPCI SCC090, Hela and HepG2 were grown to 70-80% confluence. Cells were detached using EDTA cell dissociation solution (Sigma-Aldrich, Dorset, UK), suspended in FACS buffer (PBS with 0.1% Sodium Azide, 1% bovine serum albumin), cooled on ice and centrifuged at 1000 rpm for 5 min. The supernatant was decanted and cells resuspended in cooled FACS buffer. Each cell suspension was then divided equally into three microtubes and pelleted at 2000 rpm for 2 min. Cells were resuspended in cooled FACS buffer containing either no additive, 1.0 μg ml −1 FITC-conjugated c-Met probe, or 1.0 μg ml −1 rat IgG1κ isotype control (e-Bioscience, Hatfield, UK). Each suspension was then incubated on ice and in the dark for 40 min. Following incubation, cells were pelleted at 2000 rpm for 2 min and resuspended in cold FACS buffer. A repeat centrifugation and cold FACS buffer wash was undertaken, followed by final centrifugation at 2000 rpm for 2 min, and then resuspension in cold FACS buffer. Cells were then analysed using a Calibur flow cytometer (Becton Dickinson). Flow cytometry data were interpreted using Flowing 2.5.1 software (Freeware, Turku, Finland).
Western blotting
Cell lines were grown to approximately 70% confluence. Cultures were washed in PBS and then exposed to either unstimulated fibroblast conditioned medium control, or stimulated fibroblast conditioned medium for 0 min, 20 min or 12 h. On completion of each respective incubation period, flasks were washed in cold TBS and detached using cell dissociation solution at 4°C on a rocking machine for 10 min. Cells were centrifuged at 1000 rpm for 5 min. Cell pellets were lysed on ice in 50 mM Tris-HCL pH 7.4, 250 mM NaCl, 5 mM EDTA, 0.3% Triton X-100 and EDTA-free protease inhibitor cocktail (Roche, Germany). Lysates were boiled for 5 min in an equal volume of Laemmli sample buffer, and separated using 4-15% polyacrylamide pre-cast gels (MiniProtean TGX, Bio-Rad, CA). Separated samples were transferred to a nitrocellulose membrane (Amersham Hybond ECL, GE Healthcare, Chicago), membranes blocked in 5% skimmed milk in Tris-buffered saline (pH 7.4) with 0.1% Tween-20, then incubated with either Tyr 705-phosphorylated/non-phospho specific STAT3 antibodies (Cell Signalling Technology, Danvers; both antibodies used at 1:1000 dilution) or anti-β actin control (1:10 000 dilution) in 5% bovine serum albumin/TBST overnight at 4°C. Membranes were then incubated with horseradish peroxidase conjugated secondary antibody at a dilution of 1:10 000 for 45 min and imaged using ECL reagent (GE Healthcare).
3D invasion assay
Culturex 3D invasion assays (AMS Biotechnology, Oxford, UK) were prepared following manufacturer's instructions. DENOF08 normal oral fibroblasts and cell lines were grown to 70% confluence before being trypsinized, centrifuged at 1000 rpm for 5 min, resuspended in normal media and counted. Cell suspensions were diluted to 6 × 10 4 cells ml −1 in normal media. Two further cell suspensions containing both DENOF08 normal oral fibroblasts mixed with each cell line were created in an identical manner. DENOF08 fibroblasts were mixed with each cell line at a ratio of 1:6. Cultrex invasion assays were then undertaken according to manufacturer's instructions using HPV-negative cell lines either alone, or in combination with mixed fibroblasts. DMSO vehicle or 60 nM foretinib were added to wells and after 6 days inverted lens micrographs obtained, analysed using ImageJ and number of invading cells counted as described by Rudisch et al. (21) .
Statistical analyses
Statistical analysis was undertaken using SPSS Version 22, (IBM, Chicago). A P value of <0.05 was considered statistically significant. Analysis of migration was undertaken using the Mann-Whitney U-test for non-parametric data. Analysis of proliferation was undertaken using the Student's t-test for parametric data.
Results
In 2D culture, HPV-negative OPC lines induce a fibroblast phenotype that supports tumour migration, whereas HPV-positive OPC lines do not
Fibroblast cultures stimulated by HPV-negative OPC cell lines produced conditioned media that was supportive of cancer cell migration when re-exposed to the respective stimulating carcinoma cell line. HPV-positive OPC cell lines did not stimulate a significant fibroblast response and did not induce migration ( Figure 1A) . Support of migration was consistently observed using a range of stimulated oral (DENOF08) and tonsil fibroblast cultures (NTF01, NTF06) ( Figure 1A) . Although a weak trend towards increased proliferation was noted with all stimulated fibroblast media, with cell lines UPCI SCC090 and UPCI SCC072 demonstrating significant increases (P < 0.05) in proliferation at 96 h, MTS assay demonstrated no significant difference in proliferative response of HPV-negative cell lines in comparison to HPV-positive cell lines (Figure 1B-E) .
HPV-negative OPC cell lines stimulate normal oral fibroblasts to adopt a characteristic secretory profile when compared to HPV-positive OPC lines
Cytokine array analysis of stimulated fibroblast CM was undertaken to investigate changes in the fibroblast secretome that may account for differences in cancer cell migration. Conditioned media taken from fibroblasts stimulated by HPV-negative cell lines demonstrated a characteristic secretory profile compared to HPV-positive lines (Figure 2A-D) . Densitometry of cytokine array data identified upregulation of a number of factors that signal via CXCR-1/2, including IL-8, CXCL6, CXCL5, CXCL1 and GRO (CXCL1-3; array spot non-specific to GRO subtype). HGF and IL-6 were also secreted in greater amounts by fibroblasts in response to HPV-negative compared to HPV-positive cell line stimulation, with a similar secretory profile being observed in both oral and tonsillar fibroblasts. To examine which factor(s) in stimulated fibroblast conditioned media were responsible for driving migration, dose-response analysis was undertaken on cell line UPCI SCC072 using recombinant candidate proteins identified as upregulated in the cytokine arrays. Dose-response analysis established two factors capable of driving cell line migration, namely HGF and Oncostatin M ( Figure 3A) . Subsequent ELISA analysis found Oncostatin M to be absent from stimulated fibroblast conditioned media (data not shown).
HPV-negative OPC lines induce fibroblasts to release HGF. Inhibition of HGF leads to abrogation of fibroblast support of HPV-negative cell line migration and invasion
ELISA analysis demonstrated minimal release of HGF in both OPC cell lines and fibroblasts when cultured alone ( Figure 3B ). However, stimulation of fibroblasts with cell line conditioned media led to a significant increase in HGF production, with marked HGF release by fibroblasts in response to media taken from HPV-negative cell lines when compared with fibroblasts stimulated by media from HPV-positive cell lines ( Figure 3B ). HGF secretion occurred within the first 24 h of fibroblast stimulation, and was noted to be elevated in cell line conditioned media following subsequent co-incubation with fibroblasts ( Figure 3B , 'mixed media'). Although an HGF response was observed in fibroblasts following stimulation by HPV-positive cell lines, the response was much reduced within the 24-h period post-stimulation ( Figure 3B ). Expression levels of the HGF receptor, c-Met, were comparable in all OPC lines ( Figure 3C ). c-Met activation leads to the phosphorylation of a number of intracellular signalling molecules, including STAT3. To examine secondary messenger activation of cell lines in response to stimulated fibroblast conditioned media, immunoblotting for phosphorylated (p)STAT3 was performed ( Figure 3D cell migration in response to stimulated fibroblast conditioned media at 40 nM ( Figure 4A and B) . Analysis of LDH activity in the conditioned media indicated the inhibitors were not cytotoxic at the doses used (Supplemental Data, available at Carcinogenesis Online). As foretinib has is able to inhibit EGFR (albeit comparatively weakly), cell migration experiments were repeated in normal media containing 20 ng ml −1 recombinant EGF. Incubation with 20 ng ml −1 EGF demonstrated an increase in overall migration, which was not reduced following exposure to foretinib in concentrations equal to that used to abrogate migration in stimulated fibroblast media (Supplementary Figures E and F, available at Carcinogenesis Online), indicating that EGF was not primarily responsible for fibroblast-induced migration. ELISA analysis further confirmed the absence of EGF from stimulated fibroblast media. Experiments were further repeated with the highly-specific c-MET inhibitor, INCB28060 (Capmatinib), with an identical pattern of effect to that observed with foretinib ( Supplementary  Figures G and H, available at Carcinogenesis Online). and UPCI SCC089, respectively. (C, D) Effect of addition of 1 µM ruxolitinib on cell line migration in response to stimulated fibroblast media in cell lines UPCI SCC072 and UPCI SCC089, respectively. For all experiments, n = 9, Mann-Whitney U-test utilised as measure of statistical significance, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, CM denotes stimulated fibroblast conditioned media, Ctrl denotes unstimulated control fibroblast conditioned media, Rux denotes addition of 1 µM ruxolitinib, For denotes foretinib with suffix denoting concentration in nM, DMSO denotes dimethyl suphoxide solvent control.
Invasion was observed in spheroid models when HPVnegative cell lines were co-cultured with normal fibroblasts, whereas minimal invasion was noted in cell lines in the absence of fibroblasts ( Figure 5A and C) . Cells invading into the collagen matrix demonstrated cytokeratin A1/3 positivity upon immunohistochemical analysis, confirming cell lines had invaded (Supplementary Figure D, available at Carcinogenesis Online). Exposure to 60 nM foretinib significantly (P < 0.001) reduced invasion of co-cultured HPV-negative cell lines ( Figure 5D ). Compared to HPV-negative cell lines, HPV-positive cell lines demonstrated significantly (P < 0.05) less invasion. Overall, the amount of invasion observed in all cell lines was consistent with the amount of HGF induced in fibroblast conditioned media as measured via ELISA in 2D experiments ( Figure 3B ).
IL-6/JAK activation leads to support of HGF-induced migration in HPV-negative cell lines
Due to discrepancies between ELISA-measured HGF concentration in stimulated fibroblast media linked to cell line UPCI SCC072 and the concentration of recombinant HGF required to induce the same degree of migration in the aforementioned cell line, IL-6 was investigated as a candidate molecule for supplementing HGF's effect. IL-6 was observed to be elevated in HPV-negative stimulated fibroblast media in a similar manner to HGF although addition of recombinant IL-6 alone failed to induce migration ( Figure 3A) . Addition of recombinant IL-6 to HGF potentiated HGF's effect on migration in cell line UPCI SCC072 ( Figure 6A ). Ruxolitinib, a JAK inhibitor capable of blocking IL-6 induced STAT3 activation whilst permitting continued HGF activation of STAT3 via a JAK-independent route, confirmed that inhibition of JAK activity reduced cell line responsiveness to stimulated fibroblast media ( Figure 4C and D) .
In the case of HPV-negative cell line UPCI SCC089 (observed to be unresponsive to recombinant IL-6 supplementation of HGF), inhibition of basal JAK activity was considered the mechanism through which ruxolitinib had achieved an inhibitory effectindeed, this finding is consistent with Western blot data which demonstrate basal STAT3 activation in this cell line ( Figure 3D ).
Discussion
Our data demonstrate for the first time that HPV-negative tumour lines have greater capacity compared with HPV-positive lines to rapidly induce a normal fibroblast population to produce a pro-invasive secretome. Whilst stromal support of tumour invasion has been classically ascribed to established cancerassociated fibroblasts (22) , it appears that a phenotypically mature cancer-associated stromal population is unnecessary. Although it is likely that cancer-associated fibroblasts represent a more established secretory phenotype, and may be both autonomous and more exaggerated in their factor secretion compared to the stimulated normal stroma, it is possible that senescent and myo-fibroblastic cancer-associated fibroblast populations (23) are the downstream consequence of pathways utilized to immediately recruit normal stroma into supporting tumour progression. Indeed, the capacity of a rapid fibroblast HGF-secreting response offers clear selection pressure for tumour populations to evolve towards stromal activation, whereas the more gradual process of cancer-associated fibroblast formation offers a less immediate evolutionary advantage.
A recent review has highlighted the importance of c-MET signalling in both malignant and stromal cells of the head and neck region (24) . Our work suggests that HGF upregulation is a characteristic feature of HPV-negative, but not HPV-positive OPC and may contribute to its more aggressive nature compared to HPV-positive disease. Indeed, Kwon et al. published clinical data suggesting immunohistochemical HGF status but not c-Met status is predictive of HPV-negative tumour outcomes, although neither HGF nor c-Met are predictive in HPV-positive disease (25) . This is consistent with our findings, which demonstrated comparable c-Met status in all OPC lines analyzed, in addition to fibroblast secretion of HGF supporting HPV-negative cell line migration. Whilst HPV-positive cell lines also appear to be capable of inducing a HGF response in fibroblasts, the magnitude of response in vitro is low compared to that of HPV-negative cells and may account for the lack of predictive value related to a positive HGF status in HPV-positive disease. HPV-positive disease is well-documented as presenting at a more advanced nodal stage than HPV-negative disease-whilst this observation appears counterintuitive to our in vitro findings, it should be noted that our model of HGF induction relates to additional rather than overall migration; no relationship was noted in stimulated/ unstimulated migration rates when compared between cell lines. In the case of HPV-positive disease, migratory and invasive potential may be independent of HGF, although may still remain clinically more extensive than observed in HPV-negative disease.
Our 3D invasion experiments suggest foretinib offers much promise in the management of HPV-negative OPC. Relatively modest results have been observed with foretinib in clinical trials although all current Phase II studies have investigated advanced and metastatic disease (26) (27) (28) (29) . A more appropriate strategy for the application of c-MET inhibitors may be in the management of early stage tumours, whereby obstructing migration and invasion of OPC cells may lead to reduced metastasis and more manageable local disease. Interestingly, foretinib restricted 3D co-culture invasion in similar concentrations to that observed in 2D models. This finding may be due to the fact that the functional effect of foretinib has been measured through analysis of cellular escape from a tumour spheroid surface, whereby a number of the features of 3D tumour drug resistance which often protect cells at the central core of spheroids, such as concentration gradients and hypoxic barriers, are no longer relevant. c-MET inhibitors may therefore serve as an ideal candidate for the limit of tumour spread in vivo.
We present data to support a complex interrelationship between HGF and HPV-negative OPC motility; basal JAK activity and IL-6 both appear to have a significant role in supporting cell responsiveness to HGF, and may offer potentiation of HGF signalling through common secondary messenger systems such as STAT3. Crosstalk between HGF and other signalling systems has been recognized as a major mechanism in the progression of human cancer (30); indeed, Hov et al. noted cooperation between HGF and IL-6 in supporting migration of the myeloma line INA-6 in a similar manner to that observed with cell line UPCI SC072 (31), although these investigators proposed the supporting effects of IL-6 were attributable to induction of c-Met expression rather than direct interplay of secondary messenger systems. Our finding that JAK inhibition reduces HGF responsiveness in HPV-negative cell lines suggests that JAKdependent secondary messenger systems are necessary for this supplemental effect, although we have not excluded induction of c-Met expression as the downstream mechanism through which this interaction is achieved. Ruxolitinib's effect on HPVnegative cell line migration in response to stimulated fibroblast media is consistent with the subtle differences between HGF and IL-6 induction of STAT3, and may infer a STAT3 basis of HGF/IL-6 cooperativity. This model requires further validation in the context of a number of other signalling molecules phosphorylated by JAKs. Our data suggest that c-Met inhibitors such as foretinib may be of particular clinical value as an adjuvant to current protocols in the management of early HPV-negative OPC. Restraint of early tumour invasion through HGF inhibition may create more manageable local disease in addition to reducing micro-metastasis. Further, in-vivo pre-clinical data is necessary to determine whether c-Met inhibitors have the same capacity to restrict OPC invasion using an animal model, as has been observed in-vitro.
